The Use of Recreational Cannabis Among Breast Reduction Patients: Characteristics, Complications, and Immediate Postoperative Analgesic Needs

<b>Introduction:</b> The characteristics, complications, and postoperative analgesic needs of patients with a recent or active history of recreational cannabis use have not been explored explicitly in plastic surgery. In this study, the characteristics, complications, and postoperative analgesic needs within a population of breast reduction patients who use and do not use recreational cannabis were compared. <b>Methods:</b> A retrospective cohort study was carried out on patients who underwent breast reduction between 2019 and 2023. Demographics, comorbidities, recreational cannabis use, postoperative opioid use, and postoperative complications were collected. Patients with a recent history (<1 month since last cannabis use) or current cannabis use were then compared to patients with no history of cannabis use. <b>Results:</b> In total, 340 patients were included, 88 (26%) patients had a history of cannabis use and 252 (74%) did not. Patients in the cannabis-using group were significantly younger than in the non-cannabis-using group (28 years vs 40 years, <i>P</i> < .01), and significantly more patients in the non-cannabis group had hypertension (20% vs 6% <i>P</i> < .01). More patients in the cannabis-using group had hematomas (5% vs 1%, <i>P</i> = .041) and fewer had t-point breakdown (4% vs 0%, <i>P</i> = .046), but these figures lost statistical significance on multiple logistic regression analysis after controlling for possible confounding factors including demographics and comorbidities (<i>P</i> > .05). There were no significant differences in proportions of opioid use or by doses of opioids, even when converted to oral morphine equivalents (<i>P</i> > .05). <b>Conclusion:</b> The analgesic needs, postoperative pain levels, and complications between cannabis-using and non-cannabis-using cohorts were similar. Counseling on substance use preoperatively should still be encouraged, especially in younger patients seeking reduction mammaplasty.

Authors

Institutions

Publication Details

Journal
Plastic Surgery
Published
2024-08-30
DOI
https://doi.org/10.1177/22925503241276549
Citations
4
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
1.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Use of Recreational Cannabis Among Breast Reduction Patients: Characteristics, Complications, and Immediate Postoperative Analgesic Needs

Nargiz Seyidova, Abena Gyasi, Olachi Oleru, Peter W. Henderson et al.
4 citations
Plastic Surgery
Cannabis and Cannabinoid Research
1.79
article

The Use of Recreational Cannabis Among Breast Reduction Patients: Characteristics, Complications, and Immediate Postoperative Analgesic Needs

Nargiz Seyidova, Abena Gyasi, Olachi Oleru, Peter W. Henderson, Simeret Genet, Carol Wang, Daniel Y. Kwon, Peter Shamamian, Esther Kim
article en
4 citations

Abstract

<b>Introduction:</b> The characteristics, complications, and postoperative analgesic needs of patients with a recent or active history of recreational cannabis use have not been explored explicitly in plastic surgery. In this study, the characteristics, complications, and postoperative analgesic needs within a population of breast reduction patients who use and do not use recreational cannabis were compared. <b>Methods:</b> A retrospective cohort study was carried out on patients who underwent breast reduction between 2019 and 2023. Demographics, comorbidities, recreational cannabis use, postoperative opioid use, and postoperative complications were collected. Patients with a recent history (<1 month since last cannabis use) or current cannabis use were then compared to patients with no history of cannabis use. <b>Results:</b> In total, 340 patients were included, 88 (26%) patients had a history of cannabis use and 252 (74%) did not. Patients in the cannabis-using group were significantly younger than in the non-cannabis-using group (28 years vs 40 years, <i>P</i> < .01), and significantly more patients in the non-cannabis group had hypertension (20% vs 6% <i>P</i> < .01). More patients in the cannabis-using group had hematomas (5% vs 1%, <i>P</i> = .041) and fewer had t-point breakdown (4% vs 0%, <i>P</i> = .046), but these figures lost statistical significance on multiple logistic regression analysis after controlling for possible confounding factors including demographics and comorbidities (<i>P</i> > .05). There were no significant differences in proportions of opioid use or by doses of opioids, even when converted to oral morphine equivalents (<i>P</i> > .05). <b>Conclusion:</b> The analgesic needs, postoperative pain levels, and complications between cannabis-using and non-cannabis-using cohorts were similar. Counseling on substance use preoperatively should still be encouraged, especially in younger patients seeking reduction mammaplasty.

Plastic SurgeryVol. 33(4)
Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 15%
Cannabis and Cannabinoid Research
1.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.